These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12787422)

  • 1. The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients.
    Tonelli M; Winkelmayer WC; Jindal KK; Owen WF; Manns BJ
    Kidney Int; 2003 Jul; 64(1):295-304. PubMed ID: 12787422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An economic evaluation of erythropoiesis-stimulating agents in CKD.
    Clement FM; Klarenbach S; Tonelli M; Wiebe N; Hemmelgarn B; Manns BJ
    Am J Kidney Dis; 2010 Dec; 56(6):1050-61. PubMed ID: 20932621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model.
    Borg S; Glenngård AH; Osterborg A; Persson U
    Acta Oncol; 2008; 47(6):1009-17. PubMed ID: 18770060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia.
    Papatheofanis FJ; McKenzie RS; Mody SH; Suruki RY; Piech CT
    Curr Med Res Opin; 2006 May; 22(5):837-42. PubMed ID: 16709305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing versus discontinuing erythropoietin at high hemoglobin levels.
    Weiner DE; Miskulin DC; Seefeld K; Ladik V; Zager PG; Singh AK; Johnson HK; Meyer KB
    J Am Soc Nephrol; 2007 Dec; 18(12):3184-91. PubMed ID: 17978308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Utility Analysis of Erythropoietin for Anemia Treatment in Thai End-Stage Renal Disease Patients with Hemodialysis.
    Thaweethamcharoen T; Sakulbumrungsil R; Nopmaneejumruslers C; Vasuvattakul S
    Value Health Reg Issues; 2014 May; 3():44-49. PubMed ID: 29702936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis].
    Canaud B; Polito-Bouloux C; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C
    Nephrologie; 1990; 11(1):5-10. PubMed ID: 2374643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of darbepoetin alpha in hemodialysis patients resistant to human recombinant erythropoietin (rHuEpo).
    Hejaili F
    Saudi J Kidney Dis Transpl; 2009 Jul; 20(4):590-5. PubMed ID: 19587498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa.
    Hymes J; Bickimer T; Jackson JH; Bookhart BK; Mody SH; Tak Piech C
    Curr Med Res Opin; 2007 Aug; 23(8):1931-7. PubMed ID: 17624232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of anemia in renal transplantation: impact of a stricter application of hemoglobin targets.
    Gentil MA; Pérez-Valdivia MA; González-Roncero FM; López-Mendoza M; Cabello V; Bernal G; Suñer M; Pereira P
    Transplant Proc; 2008 Nov; 40(9):2916-8. PubMed ID: 19010146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interpatient variation in response to subcutaneous versus intravenous low dose erythropoietin.
    Barclay PG; Fischer ER; Harris DC
    Clin Nephrol; 1993 Nov; 40(5):277-80. PubMed ID: 8281716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Erythropoietin and transfusions in patients with anemia of chronic renal failure origin : an update view].
    Duclos J; Olea C; Aguirre H; Alvarez MC; Salgado MC
    Rev Med Chil; 1995 Apr; 123(4):451-5. PubMed ID: 8525189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of Medicare hemodialysis patients.
    Weinhandl ED; Gilbertson DT; Collins AJ
    Am J Nephrol; 2011; 34(4):298-308. PubMed ID: 21829009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anemia in pediatric hemodialysis patients: results from the 2001 ESRD Clinical Performance Measures Project.
    Frankenfield DL; Neu AM; Warady BA; Fivush BA; Johnson CA; Brem AS
    Kidney Int; 2003 Sep; 64(3):1120-4. PubMed ID: 12911565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Erythropoietin: a study of its use in oncohematology].
    Fernández Martín JM; Villa Rubio A; Cameán Fernández M; Borrero Rubio JM; Martínez Díaz C; Díaz Navarro J; Moreno Sánchez FC; Serrano Ruiz FJ
    Farm Hosp; 2004; 28(1):20-8. PubMed ID: 15012175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perihospitalization patterns of hemoglobin levels and erythropoiesis-stimulating agent doses in US hemodialysis patients, 1998-2009.
    Foley RN; Solid CA; Lamb K
    Hemodial Int; 2014 Jan; 18(1):24-31. PubMed ID: 24131588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An economic evaluation of intravenous versus oral iron supplementation in people on haemodialysis.
    Wong G; Howard K; Hodson E; Irving M; Craig JC
    Nephrol Dial Transplant; 2013 Feb; 28(2):413-20. PubMed ID: 23182811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoietin response and route of administration.
    Taylor JE; Belch JJ; Fleming LW; Mactier RA; Henderson IS; Stewart WK
    Clin Nephrol; 1994 May; 41(5):297-302. PubMed ID: 8050210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum.
    Tsai JC; Lai YH; Tsai ZY; Chien LJ; Tsai JH
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.